Baxter International Finalizes $3.8 Billion Sale of Kidney Care Segment to Carlyle
Tuesday, 13 August 2024, 05:23
Baxter International Sells Kidney Care Segment
Baxter International Inc. (BAX) has officially agreed to sell its Kidney Care segment for $3.8 billion. This decision aims to shift the company's focus to its core operations and address the evolving needs of patients.
Details of the Agreement
- The sale will be executed through the Carlyle Group.
- The Kidney Care unit will be rebranded following the transaction.
- This move is seen as a strategic effort to enhance Baxter's financial health.
Conclusion
The divestiture marks a pivotal step for Baxter as it seeks to strengthen its market position. This sale is anticipated to generate substantial capital that will fuel future growth.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.